.

Patients on Therapy/Children on SPINRAZA

have been treated with
SPINRAZA worldwide1*

there’s someone from almost every
age group who has taken SPINRAZA1,2

have been treated with
SPINRAZA worldwide1*

*Based on commercial patients, early access patients, and clinical trial participants through December 2020.
†Includes clinical trial patients.
‡Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2020.

Some moments are ordinary. Others, memorable. Watch the real-life stories of patients on SPINRAZA

Camden // age 4 // presymptomatic SMA

“We’re just so thankful and blessed where he’s at right now.”

Sofia // age 2.5 // early-onset SMA

“She has so much joy and so much love and so much drive.”

Ruby // age 6 // later-onset SMA

“We feel like we have this tool to fight back with.”

Ashley// age 7 // later-onset SMA

“The little gains mean so much.”

Carlee // age 11 // later-onset SMA

“This is hope for her future.”

Considering SPINRAZA for your patient? Find resources for insurance, financial assistance, and more

Explore our support offerings
Start your patient on SPINRAZA

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

INDICATION

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

References

1. Biogen Data on File [as of 12/20]. 2. SPINRAZA [prescribing information]. Cambridge, MA: Biogen; 2020.

Stay Connected
Sign up with us to receive the latest news, support information, and upcoming events.

Please enter a valid email address.

ABOUT SMA
What Is SMA Multidisciplinary Care
Why SPINRAZA
About SPINRAZA How SPINRAZA Works Later-Onset Efficacy Early-Onset Efficacy Presymptomatic Efficacy Safety
Starting SPINRAZA
How to Start Find a Treatment Center Dosing & Administration
Patients on Therapy
Adults on SPINRAZA Children on SPINRAZA
Support
Access & Reimbursement SMA360°™ Patient Support

©2021 Biogen. All rights reserved.
This site is intended for US healthcare professionals only.
SPZ-US-3383 v4